Ignite Creation Date:
2024-05-06 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05728931
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-02-15
First Post:
2022-11-21
Brief Title:
New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DeNobio
Brief Summary:
Autoimmune encephalitis AE and paraneoplastic neurological syndromes PNS are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms patients can be cured by appropriate immunotherapy Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy However if some autoantibodies are now well-characterized and industrial kits have been developed to detect them in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment Furthermore as the mechanisms of AE and PNS is still unknown treatments are not optimal and in some cases inefficient There is no prognosis biomarker able to predict the patients sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients The investigators will use this project to better characterize AE and PNS patients to identify new diagnostic and prognostic biomarkers and develop new diagnostic tools
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None